Clinical Trials Logo
  1. Home
  2. Primary CNS Lymphoma
  3. NCT04947319

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

Primary CNS Lymphoma Clinical Trial

Official title:
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)

Clinical Trial Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04947319
Study type Interventional
Source Ono Pharmaceutical Co. Ltd
Contact Ono Pharma USA, Inc.
Phone 6179044500
Email PROSPECTstudy@ono-pharma.com
Status Recruiting
Phase Phase 2
Start date December 29, 2021
Completion date March 31, 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05036564 - Diagnosis; Objective RespOnse; THErApy N/A
Recruiting NCT03569995 - [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma Phase 2
Recruiting NCT04627753 - Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. Phase 2
Recruiting NCT05518383 - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Phase 4
Recruiting NCT05425654 - RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL Phase 2
Terminated NCT04073147 - Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma Phase 1
Active, not recruiting NCT04443829 - Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma Phase 1
Recruiting NCT04006561 - Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
Recruiting NCT04656431 - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma Phase 1
Active, not recruiting NCT04464200 - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Phase 1
Recruiting NCT02934204 - Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Phase 2
Active, not recruiting NCT04134117 - Tisagenlecleucel In Primary CNS Lymphoma Phase 1
Withdrawn NCT03212807 - Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL Phase 2